3728 Jinke Rd, Bldg 1, West Wing, Shanghai, China
info@tyligand.com
Tyligand Bioscience completed A round of financing
Shanghai, 2021-5-20. Tyligand Bioscience, which is committed to the research and development of new small molecule anti-tumor drugs, announced the completion of the A round of financing of about US$20 million jointly participated by Hongli Venture Capital, Yijing Capital, and China Medical System. This round of financing will be used to promote the transformation of the company's pipeline to the clinical stage, including the phase II clinical trials of onapristone in China, the preclinical research and IND declaration of 3 innovative molecules, and several First-in-class research projects compound optimization. BFC Capital acted as the exclusive financial advisor to Tyrex in this transaction.
Dr. Zhang Yantao, chairman of Tyligand Bioscience, said: I am very grateful to new and old investors for their recognition and support of Tyligand's original creativity. We should live up to high expectations, strive to efficiently promote the progress of the pipeline, develop high-quality first-class new drugs that can stand the test of time, and provide patients and medical staff with more accessible and reliable treatment options.
Dr. Xu Tianhong, managing partner of Holly Ventures, said: Holly Ventures is committed to discovering and investing in original innovations in the field of biomedicine at home and abroad, as well as first-class entrepreneurial teams of scientists with a solid style and deep foundation. Tyligand's unique First-in-class and Best-in-class R&D pipeline is the best proof of its team's creativity and execution ability in drug molecule design. We look forward to working closely with the company in the field of life sciences to provide safe and effective treatment options for cancer patients.
Yijing Capital said: Tyligand team has become one of the most innovative companies in the field of small molecules with its global vision in risk management and control, decision-making power in target selection, and efficient capital utilization. Yijing Capital is very optimistic about the company's R&D platform built around the selective regulation of molecular phosphorylation levels, and is also very honored to support the advancement of Tyrena's pipeline and the realization of clinical value. It looks forward to the smooth progress of the company's products under research and the early benefit of patients around the world.
Lin Gang, Chairman of CMS, said: Tyligand has a strong team, and its research pipeline is unique and highly competitive, and it has also attracted first-class collaborators. It is a great pleasure to join hands with investment partners to jointly support original innovations that the market desperately needs.
Tyligand Bioscience is a pragmatic and efficient small molecule new drug innovation engine, co-founded in 2018 by molecular designers of new drugs with excellent records, experienced executives of multinational pharmaceutical companies, and international academic leaders in the field of phosphatases. Previous round investors include Yuanhe Yuandian, Mifang Capital, Mint Angel and Xianfeng Changqing. Based on the ability of synthetic chemistry to explore new molecular space, combined with scientific insights into biological targets and rich experience in drug development, the team has established a unique anti-tumor molecular pipeline, with indications covering lung cancer, colorectal cancer, hormone-driven Tumors, and a variety of solid tumors.
Dr. Zhang Yantao, chairman of Tyligand Bioscience, said: I am very grateful to new and old investors for their recognition and support of Tyligand's original creativity. We should live up to high expectations, strive to efficiently promote the progress of the pipeline, develop high-quality first-class new drugs that can stand the test of time, and provide patients and medical staff with more accessible and reliable treatment options.
Dr. Xu Tianhong, managing partner of Holly Ventures, said: Holly Ventures is committed to discovering and investing in original innovations in the field of biomedicine at home and abroad, as well as first-class entrepreneurial teams of scientists with a solid style and deep foundation. Tyligand's unique First-in-class and Best-in-class R&D pipeline is the best proof of its team's creativity and execution ability in drug molecule design. We look forward to working closely with the company in the field of life sciences to provide safe and effective treatment options for cancer patients.
Yijing Capital said: Tyligand team has become one of the most innovative companies in the field of small molecules with its global vision in risk management and control, decision-making power in target selection, and efficient capital utilization. Yijing Capital is very optimistic about the company's R&D platform built around the selective regulation of molecular phosphorylation levels, and is also very honored to support the advancement of Tyrena's pipeline and the realization of clinical value. It looks forward to the smooth progress of the company's products under research and the early benefit of patients around the world.
Lin Gang, Chairman of CMS, said: Tyligand has a strong team, and its research pipeline is unique and highly competitive, and it has also attracted first-class collaborators. It is a great pleasure to join hands with investment partners to jointly support original innovations that the market desperately needs.
Tyligand Bioscience is a pragmatic and efficient small molecule new drug innovation engine, co-founded in 2018 by molecular designers of new drugs with excellent records, experienced executives of multinational pharmaceutical companies, and international academic leaders in the field of phosphatases. Previous round investors include Yuanhe Yuandian, Mifang Capital, Mint Angel and Xianfeng Changqing. Based on the ability of synthetic chemistry to explore new molecular space, combined with scientific insights into biological targets and rich experience in drug development, the team has established a unique anti-tumor molecular pipeline, with indications covering lung cancer, colorectal cancer, hormone-driven Tumors, and a variety of solid tumors.
About Hongli Ventures
Holly Ventures focuses on companies with entrepreneurial passion, mainly investing in medical technology, life science and TMT fields, and its investment scope covers China, the United States and Israel. We help overseas companies in our portfolio enter the booming Chinese market, and at the same time build a bridge for domestic companies to expand their business overseas. As a boutique investment firm, we provide seed, start-up and growth stage funding. At the same time, we provide our portfolio companies with professional services in the indispensable aspects of branding, marketing, channel development, cross-border expansion, human resources and finance.
About Yijing Capital
Founded in 2015, Yijing Capital conducts primary market equity investment and parent fund investment with its own funds and private equity funds. Adhering to the concept of "helping enterprises innovate and grow, promoting industrial optimization and upgrading, and promoting social development and progress", Yijing Capital focuses on medical health, hard-core technology, TMT & big consumption and other fields, focusing on investing in high-value creation and high-tech innovation start-ups In the medical field, it has invested in a number of industry-leading companies in subdivided industries, including Zhidao Biotechnology, OPMed, Hanyu Medical, Dayi Group, Weiernuo Pediatrics, and Mayes Medical.
About China Medical System
China Medical System is a professional pharmaceutical company driven by global innovation and focusing on the Chinese market. China Medical System focuses on the layout of innovative drugs that are the first in the world, or have innovative preparations and innovative drug delivery methods to achieve the best, safest, or most cost-effective ratio of similar treatments; Innovation pipeline for competitive differentiation. China Medical System has more than 20 years of proven successful drug promotion experience, and has a leading market position in many drugs on sale. China Medical System has become one of the companies with the highest management efficiency in China's pharmaceutical industry driven by strong product strength, strong sales promotion capabilities, and a professional, efficient, and refined internal management system.
Founded in 2018, Tyligand Bioscience is a clinical-stage biotechnology company focused on the discovery and development of cancer therapeutics to address drug resistant tumors. Leveraging deep insights into the chemistry of biomolecule phosphorylation, the company has efficiently built a differentiated pipeline and technology platforms including 1st-in-class Dual Action Tumor Immune Agonist (DATIA®) assets and a novel platform for ADC payload design and development.
- Tyligand Bioscience (Shanghai) Limited